6533b85dfe1ef96bd12bf215
RESEARCH PRODUCT
Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course
Lorenzo CavagnaErnesto Trallero-araguásFederica MeloniIlaria CavazzanaJorge Rojas-serranoEugen FeistGiovanni ZanframundoValentina MorandiAlain MeyerJose Antonio Pereira Da SilvaCarlo Jorge Matos CostaOyvind MolbergHelena AnderssonVeronica CodulloMarta MoscaSimone BarsottiRossella NeriCarlo ScirèMarcello GovoniFederica FuriniFrancisco Javier Lopez-longoJulia Martinez-barrioUdo SchneiderHanns-martin LorenzAndrea DoriaAnna GhirardelloNorberto Ortego-centenoMarco ConfalonieriPaola TomiettoNicolò PipitoneAna Belen Rodriguez CambronMaría ÁNgeles Blázquez CañameroReinhard Edmund VollSarah WendelSalvatore ScarpatoFrancois MaurierMassimiliano LimontaPaolo ColombelliMargherita GianniniBernard GenyEugenio ArrigoniElena BraviPaola MiglioriniAlessandro MathieuMatteo PigaUlrich DrottChristiane DelbrueckJutta BauhammerGiovanni CagnottoCarlo VancheriGianluca SambataroEllen De LanghePier Paolo SainaghiMaria Cristina MontiFrancesca Gigli BerzolariMariaeva RomanoFrancesco BonellaChristof SpeckerAndreas SchwartingIgnacio Villa BlancoCarlo SelmiAngela CeribelliLaura NunoAntonio Mera-varelaNair Perez GomezEnrico FusaroSimone ParisiLuigi SinigagliaNicoletta Del PapaMaurizio BenucciMarco Amedeo CimminoValeria RiccieriFabrizio ContiGian Domenico SebastianiAnnamaria IulianoGiacomo EmmiDaniele CammelliMarco SebastianiAndreina ManfrediJavier Bachiller-corralWalter Alberto Sifuentes GiraldoGiuseppe PaolazziLesley Ann SaketkooRoberto GiorgiFausto SalaffiJosé Manuel CifriánRoberto CaporaliFrancesco LocatelliEnrico MarchioniAlberto PesciGiulia DeiMaria Rosa PozziLomater ClaudiaJorg DistlerJohannes KnitzaGeorge SchettFlorenzo IannoneMarco FornaroFranco FranceschiniLuca QuartuccioRoberto GerliElena BartoloniSilvia Bellando RandoneGiuseppe ZampognaMontserrat I. Gonzalez PerezMayra MejiaEsther VicenteKonstantinos TriantafylliasRaquel Lopez-mejiasMarco Matucci-cerinicAlbert Selva-o'callaghanSantos CastañedaCarlomaurizio MontecuccoMiguel A. Gonzalez-gayUniversitat Autònoma De Barcelonasubject
medicine.medical_specialtyantisynthetase antibodies; antisynthetase syndrome; arthritis; interstitial lung disease; myositisantisynthetase syndrome; antisynthetase antibodies; arthritis; myositis; interstitial lung diseaseMedizinArthritislcsh:MedicineAntisynthetase syndromeInterstitial lung diseaseAntisynthetase syndromeArticleNO03 medical and health sciences0302 clinical medicineInternal medicinemedicineantisynthetase antibodiesantisynthetase antibodies antisynthetase syndrome arthritis interstitial lung disease myositisddc:610Myositis030203 arthritis & rheumatologyinterstitial lung diseaseAntisynthetase antibodiesbiologyMyositisbusiness.industryArthritislcsh:RInterstitial lung diseaseAutoantibodyGeneral Medicinemedicine.diseasearthriti030228 respiratory systemarthritisTime courseCohortbiology.proteinAntibodyantisynthetase syndromebusinessantisynthetase antibodiemyositisdescription
Antisynthetase syndrome (ASSD) is a rare clinical condition that is characterized by the occurrence of a classic clinical triad, encompassing myositis, arthritis, and interstitial lung disease (ILD), along with specific autoantibodies that are addressed to different aminoacyl tRNA synthetases (ARS). Until now, it has been unknown whether the presence of a different ARS might affect the clinical presentation, evolution, and outcome of ASSD. In this study, we retrospectively recorded the time of onset, characteristics, clustering of triad findings, and survival of 828 ASSD patients (593 anti-Jo1, 95 anti-PL7, 84 anti-PL12, 38 anti-EJ, and 18 anti-OJ), referring to AENEAS (American and European NEtwork of Antisynthetase Syndrome) collaborative group's cohort. Comparisons were performed first between all ARS cases and then, in the case of significance, while using anti-Jo1 positive patients as the reference group. The characteristics of triad findings were similar and the onset mainly began with a single triad finding in all groups despite some differences in overall prevalence. The "ex-novo" occurrence of triad findings was only reduced in the anti-PL12-positive cohort, however, it occurred in a clinically relevant percentage of patients (30%). Moreover, survival was not influenced by the underlying anti-aminoacyl tRNA synthetase antibodies' positivity, which confirmed that antisynthetase syndrome is a heterogeneous condition and that antibody specificity only partially influences the clinical presentation and evolution of this condition. ispartof: JOURNAL OF CLINICAL MEDICINE vol:8 issue:11 ispartof: location:Switzerland status: published
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2019-11-18 |